4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial

from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/

Episode metadata supplied by the publisher feed · Published Jun 4, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial

0:00 18:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 18 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on June 4, 2022.

Can I download this Plenary Session - inactive due to federal service episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!